CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer

By sjmartinez • March 23, 2024

Lim RJ, Salehi-Rad R, Tran LM, Oh MS, Dumitras C, Crosson WP, Li R, Patel TS, Man S, Yean CE, Abascal J, Huang Z, Ong SL, Krysan K, Dubinett SM, Liu B. CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell Rep Med. 2024 Mar 19:101479. doi: 10.1016/j.xcrm.2024.101479. Epub ahead of print. PMID: 38518770.

Tags: Checkpoint blockade, CXCL10, CXCL9, CXCR3, dendritic cells, Fellow, Hematology/Oncology, immunosuppression, in situ vaccination, NSCLC, Publications, Pulmonary, Critical Care & Sleep Medicine, Resident, systemic immunity, T cells, Veterans Administration

Related Posts

Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales MA,[...]

Chemopreventive strategies for sporadic colorectal cancer: a narrative review

Monson S, Chen PJ, Gangi A, Waters K, Billet S, Hendifar A, Lu S, Zell JA, Gong J. Chemopreventive strategies for sporadic colorectal cancer: a[...]

STING directly interacts with PAR to promote apoptosis upon acute ionizing radiation-mediated DNA damage

Sun Y, Aliyari SR, Parvatiyar K, Wang L, Zhen A, Sun W, Han X, Zhang A, Kato E, Shi H, De Schutter E, McBride WH,[...]